Astrocytoma, IDH-Mutant, Grade 2 — knowledge graph · CancerIndex

Knowledge graph · Cancer

Astrocytoma, IDH-Mutant, Grade 2

molecular subtype

Identifier: CI-CAN-00007242
Entity page: /cancer/astrocytoma-idh-mutant-grade-2 ↗
Edges: 17

Neighbours: 9 drugs8 trials
Drawn: 17 of 17 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Astrocytoma, IDH-Mutant, Grade 2 investigated in trials for …INVESTIGATED_IN_TRIALSderived9 of 9
→ investigated in trials for	Safusidenibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Astrocytoma, IDH-Mutant, Grade 2	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants

Astrocytoma, IDH-Mutant, Grade 2 studied in …STUDIED_INderived8 of 8
→ studied in	NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03528642Phase 1 · active not recruiting Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07703436Phase 2 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06860594Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303519Phase 3 · recruiting SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07712757Phase 3 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07673666completed GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05190172NA · recruiting PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas · condition mapped ALIAS · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →